"Checkpoint Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine/threonine-specific protein kinase which is encoded by the CHEK1 gene in humans. Checkpoint kinase 1 (also known as Chk1) coordinates DNA damage response and cell cycle checkpoint response. Under these conditions, activation of Chk1 results in the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair and cell death, to prevent damaged cells from progressing through the cell cycle.
| Descriptor ID |
D000071877
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.143
|
| Concept/Terms |
Checkpoint Kinase 1- Checkpoint Kinase 1
- Chk1 Kinase
- Chk1 Protein Kinase
- Protein Kinase, Chk1
- Checkpoint-1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Checkpoint Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Checkpoint Kinase 1".
This graph shows the total number of publications written about "Checkpoint Kinase 1" by people in this website by year, and whether "Checkpoint Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Checkpoint Kinase 1" by people in Profiles.
-
Genetic vulnerabilities upon inhibition of DNA damage response. Nucleic Acids Res. 2021 08 20; 49(14):8214-8231.
-
Genetic insights into biological mechanisms governing human ovarian ageing. Nature. 2021 08; 596(7872):393-397.
-
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatr Blood Cancer. 2021 09; 68(9):e29065.
-
Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. J Biol Chem. 2021 Jan-Jun; 296:100382.
-
Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40.
-
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.
-
CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797.
-
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
-
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014 Sep; 16(9):864-75.
-
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Jul 30; 5(14):5637-50.